<DOC>
	<DOCNO>NCT02679755</DOCNO>
	<brief_summary>A study palbociclib combination letrozole treatment post-menopausal woman hormone receptor-positive , her2-negative advance breast cancer letrozole therapy deem appropriate .</brief_summary>
	<brief_title>Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+ , HER2- Advanced Breast Cancer</brief_title>
	<detailed_description>To provide access palbociclib post-menopausal patient hormone receptor-positive [ HR ( + ) ] , HER2-negative [ HER2 ( - ) ] ABC deem appropriate letrozole therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Postmenopausal woman ( &gt; =18 year age ) proven diagnosis advance carcinoma breast ( ER ( + ) and/or PgR ( + ) HER2 ( ) ) appropriate letrozole therapy ( firstline advanced/metastatic disease set ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Adequate bone marrow , liver , renal function . Prior treatment CDK inhibitor . QTc &gt; 480 msec ; history QT syndrome , Brugada syndrome know history QTc prolongation , Torsade de Pointes . High cardiovascular risk , include , limited myocardial infarction , severe/unstable angina , severe cardiac dysrhythmias , symptomatic pulmonary embolism past 6 month enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hormone receptor positive advance breast cancer</keyword>
</DOC>